

Special Issue

Bioengineering of Biotherapeutics

Message from the Guest Editor

Bioengineering is currently soliciting manuscripts for a Special Issue focusing on novel manufacturing methods (recombinant or chemical methods) to develop antibody-based therapeutics. Manuscripts can include literature reviews as well as primary research papers. Topics of particular interest include platforms for discovery/development of antibodies, antibody fragments, bispecific antibodies, and antibody–drug conjugates. Different strategies for manufacturing, characterization, and formulation of biotherapeutic with focus on purity, yield, and binding are particularly encouraged.

Guest Editor

Dr. Hanieh Khalili

School of biomedical science, University of West London, London W5 5RF, UK

Deadline for manuscript submissions

closed (25 November 2022)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/110769

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.